Search
Rifaximin
go.drugbank.com/drugs/DB01220ApprovedInvestigationalRifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered … It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: RIFAXIGAL® 100MG/5ML POLVO PARA RECONSTITUIR A SUSPENSION ORALATL1102
go.drugbank.com/drugs/DB04997InvestigationalATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
AAV-RPE65
go.drugbank.com/drugs/DB18343ExperimentalAAV-RPE65 is an adenovirus associated viral vector serotype 5 containing the human RPE65 gene
Synonyms: AAV-RPE65Bupranolol
go.drugbank.com/drugs/DB08808ExperimentalBupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesTAK-428
go.drugbank.com/drugs/DB05499ExperimentalTAK-428 is a drug for treating diabetic neuropathy. … It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
APL-9
go.drugbank.com/drugs/DB16460InvestigationalIt shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.
Ketazolam
go.drugbank.com/drugs/DB01587ApprovedWithdrawnKetazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesHomatropine methylbromide
go.drugbank.com/drugs/DB00725ApprovedHomatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics.
Fusafungine
go.drugbank.com/drugs/DB08965ApprovedWithdrawnFusafungine is an antibiotic from Fusarium lateririum, and is used for the treatment of respiratory infections.